{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire

  1. Asian Indians have been found to develop cardiovascular diseases at young age than Caucasians *

  2. Asian Indians have a unique pattern of dyslipidemia characterized by *

  3. South Asians manifest CVD at lower levels of total cholesterol compared with other ethnic groups *

  4. Considering the higher CV mortality in our country, do you feel threshold for various cholesterol levels to initiate treatment should be lower than western counterparts *

  5. Do you believe that elevated LDL Cholesterol is an important cause of coronary cause of coronary artery disease and ischemic stroke? *

  6. How many Patients do you encounter with Dyslipidemia in your daily practice? *

  7. Right down the % of patients having following risk factors along with dyslipidemia in your daily practice? *

    8. %

    %

    %

    %

    %
  8. Which Method do you use to stratify cardiovascular risk in your patients? *

  9. What is your choice of Statin for Primary Prevention ? Please mention the use in % *

    10. %

    %

    %
  10. Do you prescribe statin to all diabetic patients above 50 years with multiple risk factors, but not CHD *

  11. Which statin do you prefer for diabetic patients? *

  12. What is your preferred drug option for patients with LDL >160 mg /dL, TG 200-499 mg /dL, and HDL < 40mg/dL without CHD or CHD risk equivalent? *
    (Give order of preference in case of multiple options)
    13. Molecule /Drug Preference

  13. What LDL-C targets or Goals do you prefer for your patients of primary prevention? *

  14. If LDL-C goal is achieved do you also keep the non-HDL-C target? *

  15. Do you alter existing therapy to attain non-HDL-C goal in patients with LDL levels at Goal *

  16. If yes, then which is your preferred strategy to attain non-HDL-C goal in these patients *

  17. The combination of high levels of Lp(a) and homocysteine, and high prevalence of diabetes, metabolic syndrome, and Asian Indian Dyslipidaemia- and the synergistic interaction among these risk factors-best explains the high prevalence of premature, severe, diffuse, multi-vessel malignant CAD among Indians globally ( Do you agree / Disagree) *

  18. Patients with postoperative Myocardial Infarction receiving dual anti-platelet therapy in combination with Statin therapy has improved survival rates by *

  19. In approximately what % of your patients do you recommend hs-CRP testing? *

  20. What is your choice of statin for secondary prevention? *

  21. The Key components of Anti-thrombotic therapy for ACS patients include *

  22. In your opinion fixed dose combinations of statin and anti-platelet drugs have the following advantage *

  23. Fixed dose combinations of statin and anti-platelet drugs improve patient compliance and adherence *

  24. In your ACS Patients; for how long do you prefer Statin + DAPT Combination *

  25. In your opinion, is Rosuvastatin and Clopidogrel combination therapy beneficial for more effective management of Cardiovascular disease ? *

  26. Do you agree that early intensive Rosuvastatin use in ACS patients if effective in improving 12-month Outcomes? *

  27. Triple drug therapy with dual anti-platelet therapy and lipid lowering statin helps in *

  28. Triple fixed dose combination therapy of Aspirin, Clopidogrel and Rosuvastatin was the most preferred choice of physicians, for optimal management Post ACS Patient in Indian Setting *

  29. In Your opinion, usage pattern of Fixed dose combination of Rosuvastatin 10 mg + Clopidogrel 75 mg + Aspirin 75 mg dose once daily for 1-3 years is recommended for ACS patients *

  30. Combination of Clopidogrel with statin has synergistic effects on the clinical outcomes of patients with ACS *